AZ Fasenra shows benefit in chronic rhinosinusitis with nasal polyps
The drug reduced the size of nasal polyps and reduced nasal blockage
Read More
Tag: CRSwNP
Sanofi, Regeneron’s Dupixent shines in rhinosinusitis with nasal polyps trials
Sanofi and Regeneron have unveiled top-line data showing that two late-stage studies of Dupixent in adults with inadequately-controlled chronic rhinosinusitis with nasal polyps met all their primary and secondary endpoints.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
